GABRIELE ZAMPERLINI NETTO

Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/36 - Laboratório de Pediatria Clínica, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 11
  • conferenceObject
    PRIMARY CARDIAC TUMORS IN CHILDREN: A SINGLE INSTITUTION CASE SERIES
    (2022) ZAMPERLINI-NETTO, Gabriele; CRISTOFANI, Lilian; VELLASCO, Andressa; GONCALVES, Fernanda; BUENO, Gabrielle; TEIXEIRA, Roberto; ODONE FILHO, Vicente
  • conferenceObject
    Biphenotypic Acute Leukemia: Results From a Group of Patients Treated at a Single Hospital
    (2020) KROHLING, D.; GUEDES, G.; CORREA, A.; SILVA, M.; GOMEZ, K.; NERO, L. Del; BREVIGLIERI, C.; ZAMPERLINI-NETTO, G.; ALMEIDA, M.; ODONE-FILHO, V.; CRISTOFANI, L.
  • conferenceObject
    RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME: SINGLE INSTITUTION RETROSPECTIVE STUDY
    (2022) MACHADO, Ana Rahal Guaragna; FLORES, Angelica Hidalgo; SILVA, Aline Rodrigues Da; ZAMPERLINI-NETTO, Gabriele; BECHARAMAFRA, Ana; BARBUTO, Tomas Marzagao; CRISTOFANI, Lilian; ODONE FILHO, Vicente; GARCIA, Julia Lopes; FERNANDES, Juliana Folloni
  • conferenceObject
    Relapsed Acute Lymphoblastic Leukemia and Blinatumomab: Results From a Single Institution in Brazil Universidade de Sao Paulo
    (2020) ZAMPERLINI-NETTO, G.; FONSECA, M.; ALMEIDA, M.; ODONE-FILHO, V.; TEIXEIRA, R.; FERNANDES, J.; AZAMBUJA, A.; DUTRA, A.; BREVIGLIERI, C.; CRISTOFANI, L.
  • conferenceObject
    LONG TERM COMPLICATIONS IN CHILDREN TREATED FOR ADVANCED NEUROBLASTOMA
    (2012) HALLEY, Nathalia; CRISTOFANI, Lilian Maria; ALMEIDA, Maria Teresa Assis; MALUF-JUNIOR, Paulo Taufi; CORNACCHIONI, Ana Lucia Beltrati; TEIXEIRA, Roberto Augusto Plaza; ZAMPERLINI-NETO, Gabriele; GOMES, Alessandra Araujo; ODONE-FILHO, Vicente
    Purpose: Advanced neuroblastoma (stage 3 and 4) requires aggressive treatment, including surgery, chemo and radiotherapy and autologous bone marrow transplantation. Although long term survival rates are disappointing, those children who survive are prone to develop long term complications. Our aim is to report the long term complications rate and quality in children treated for stage 3 and 4 neuroblastoma. Methods: The charts of stage 3 and 4 children with neuroblastoma treated from January/1983 through October/2003 were reviewed and those surviving and with no evidence of disease for more than 5 years were selected. Late effects were classified as second malignancies, endocrinological, neuromotor, hepatic, sensorial, benign tumors, infectious diseases and psychiatric disease and others. Associations with treatment modalities were disclosed. Results: Among 263 children with stage 3 and 4 neuroblastoma, 40 (15%) are long term survivors. 20/40 (50%) present one or more complications, being 2 (10%) second malignant neoplasia, 4 (20%) endocrinological disturbances, 4 (20%) neuromotor, 5 (25%) hepatic, 4 (20%) sensorial, 3 (1.1%) benign tumors, and infertility, psychiatric disease and hepatitis C infection in 1 (5%) episode each. 10/20 (50%) of the children were less than 18 months at diagnosis, and 12/20 (60%) were stage 3 and 8/20 (40%) were stage 4. All children were submitted to chemotherapy and 7/20 (35%) to autologous bone marrow transplantation. In 10/20 (50%) patients radiotherapy was also included, and 4/10 (40%) presented functional lesions in the irradiated field. All endocrinologic sequelae were detected in the ABMT group. Second malignant neoplasia were not related to RDT(1 ALL and 1 thyroid carcinoma). Conclusion: Children surviving aggressive therapy for neuroblastoma are at risk of late effects, particularly endocrinological and neurological complications, requiring close observation to prompt intervention when necessary, avoiding impairments in quality of life or even life threatening situations. Second malignant neoplasia require special concern.
  • article 0 Citação(ões) na Scopus
    Acute promyelocytic leukemia in childhood and adolescence: treatment results of a modified AIDA protocol at a Brazilian center
    (2023) BREVIGLIERI, Carla Nolasco Monteiro; ALMEIDA, Maria Tereza Assis de; NETO, Gabriele Zampelini; TEIXEIRA, Roberto Augusto Plaza; ODONE-FILHO, Vicente; CRISTOFANI, Lilian Maria
    Introduction: Acute promyelocytic leukemia currently presents an excellent chance of cure with protocols based on all-trans-retinoic acid (ATRA) and anthracycline or only differentiation agents. However, high early mortality rates continue to be reported Methods: Between 2000 and 2018, patients were enrolled and retrospectively analyzed by medical records. A modified AIDA protocol, with a 1-year shortening of the treatment duration, reduction in the number of drugs and a strategy to reduce early mortality by the postponement of the initiation of anthracyclines were employed. Overall and event-free survival rates and toxicity were analyzed Results: Thirty-two patients were enrolled, of whom 56% were female, with a median age of 12 years and 34% belonged to the high-risk group. Two patients had the hypogranular variant and three had another cytogenetic alteration, in addition to the t(15;17). The median start of the first anthracycline dose was 7 days. There were two early deaths (6%) due to central nervous system (CNS) bleeding. All patients achieved molecular remission after the consolidation phase. Two children relapsed and were rescued by arsenic trioxide and hematopoietic stem cell transplantation. The presence of disseminated intravascular coagulation (DIC) at diagnosis (p = 0.03) was the only factor with survival impact. The five-year event-free survival (EFS) was 84% and 5-year overall survival (OS) was 90% Conclusion: The survival results were comparable to those found in the AIDA protocol, with a low rate of early mortality in relation to the Brazilian reality. (C) 2022 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • conferenceObject
    Blinatumomab (BLINA) as Sole Therapy for Relapsed Acute Leukemia (ALL) after Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
    (2020) PEREIRA, P.; VINCE, C.; BRUMATTI, M.; HALLEY, N.; AZAMBUJA, A.; FERNANDES, J.; HAMERSCHLAK, N.; ZAMPERLINI-NETTO, G.; PEREIRA, A.; KROHLING, D.; ODONE-FILHO, V.
  • conferenceObject
    OUTCOMES FOLLOWING RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH ALL: A SINGLE-CENTER EXPERIENCE
    (2022) MACHADO, Ana Rahal Guaragna; SANTOS, Camila Noronha; SION, Julia Loureiro; MORIKAWA, Karina Morikawa; ZAMPERLINI-NETTO, Gabriele; CRISTOFANI, Lilian; ODONE FILHO, Vicente; GOMES, Alessandra Araujo; FERNANDES, Juliana Folloni; GARCIA, Julia Lopes
  • bookPart
    Linfo-histiocitose hemofagocítica e síndrome de ativação macrofágica
    (2023) ELIAS, Adriana Maluf; ZAMPERLINI NETTO, Gabriele; ZAMPERLINI, Marcela Preto
  • conferenceObject
    Hydroxyurea (HU) Therapy for Patients With Post-Transplant Lymphoproliferative Disease (PTLD): Treatment and Prevention of New Episodes
    (2020) PEREIRA, P.; VINCE, C.; AZAMBUJA, A.; BRUMATTI, M.; CRISTOFANI, L.; HALLEY, N.; PEREIRA, A.; ZAMPERLINI-NETTO, G.; GUEDES, G.; ODONE-FILHO, V.